Filing identity and reporting period
The supplied filing is Global Medical REIT Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 8, 2020. This does not match the request metadata naming Chiron Real Estate Inc.; verify the intended company and filing before relying on this summary.
Global Medical REIT acquires purpose-built healthcare facilities and leases them to healthcare systems and medical providers. At quarter-end, its portfolio comprised 72 facilities and approximately 3.1 million rentable square feet.
Financial results and position
Amounts below are in millions of dollars unless otherwise indicated. Results compare the three months ended March 31, 2020 with the same 2019 period.
| Metric | Q1 2020 | Q1 2019 / prior date |
|---|---|---|
| Total revenue | $21.6 | $15.2 |
| Net income | $2.8 | $2.0 |
| Net income attributable to common stockholders | $1.3; $0.03 per share | $0.5; $0.02 per share |
| FFO per share and unit (non-GAAP) | $0.19 | $0.17 |
| AFFO per share and unit (non-GAAP) | $0.20 | $0.17 |
| Cash from operating activities | $12.3 | $6.1 |
| Cash used in investing activities | $(68.8) | $(22.7) |
| Cash from financing activities | $66.2 | $15.0 |
| Cash and restricted cash, March 31 | $16.9 | $3.3 |
| Total debt, net, March 31 | $464.5 | $386.2 at December 31, 2019 |
| Total assets / total equity, March 31 | $956.2 / $438.8 | $884.9 / $460.4 at December 31, 2019 |
Revenue rose 42% year over year, primarily reflecting properties acquired since March 2019 and a full quarter of revenue from earlier acquisitions. Net income increased 38%; common-stockholder income also benefited from the larger portfolio, while share count was substantially higher year over year. The filing does not provide a single headline operating-margin measure.
Four acquisitions added approximately $69.2 million to gross real estate investment during the quarter. The portfolio’s gross real estate investment was $974.7 million at March 31. Net borrowings under the credit facility were $78.1 million; the net facility balance was $425.8 million. The weighted-average debt interest rate was 3.63% at quarter-end, and the company reported compliance with its debt covenants.
Cash from operations increased, while investment outflows rose with acquisition activity. Financing included net credit-facility borrowing; unlike Q1 2019, the company had no common-equity offering in Q1 2020. Common dividends were $0.20 per share for the quarter, and preferred dividends were $1.455 million. The filing reports no assurance that future dividends will be maintained.
Material changes and unusual items
- Operating expenses, depreciation and amortization, and related-party management fees increased alongside portfolio growth. Interest expense rose to $4.4 million from $4.0 million, mainly due to higher average borrowings.
- The company recorded a $0.5 million management-internalization expense and $0.05 million of preacquisition fees in Q1 2020.
- Interest-rate swaps produced a $14.0 million other-comprehensive loss, increasing accumulated other comprehensive loss. The swaps’ net liability was $20.5 million at March 31, versus $6.5 million at year-end. The company estimated a further $5.6 million would be reclassified as increased interest expense over the next 12 months.
- Common shares outstanding increased from 43.8 million at year-end to 44.3 million at March 31, partly reflecting conversion of OP and LTIP units. The 2019 comparison also included significant equity issuance.
Outlook, commentary, and risks
- Management said COVID-19 had not materially affected Q1 results or liquidity as of March 31, but the future impact was uncertain. As of April 30, the company estimated $2 million of rent due April–July would be deferred, primarily for collection July–December 2020, and expected to collect substantially all of it. Tenant payment ability and any further relief requests remained uncertain.
- As of April 30, cash and available credit-facility capacity totaled approximately $70 million. Management believed existing liquidity and operating cash flow could meet short-term needs under its expected rent-deferral scenario; continued acquisitions and a possible management internalization would require access to additional financing.
- Management cited reduced tenant patient volumes, restrictions on elective procedures, unemployment and loss of health coverage, tenant credit and rent-collection risk, constrained capital-market access, and a reduced acquisition pipeline. It said it could not estimate COVID-19’s eventual operational impact. No formal earnings or acquisition guidance is provided.
- Management reported approximately $130 million of 2020 acquisitions completed or under contract as of the report date; the filing also disclosed three properties under contract for about $45.1 million, subject to due diligence. A post-quarter acquisition in Dumfries, Virginia, had a $19.25 million purchase price.
- Negotiations over a potential management internalization continued; any agreement would require further approval. The company disclosed no material pending litigation and reported effective disclosure controls.
- Interest-rate exposure includes $129.5 million of unhedged variable-rate revolver borrowings; a 100-basis-point LIBOR increase was estimated to reduce annual cash flow by approximately $1.3 million, assuming debt levels were unchanged. LIBOR transition and tenant credit risks are also noted.
Important facts for investors to verify
- Confirm the filing is for Global Medical REIT Inc. (NYSE: GMRE), not Chiron Real Estate Inc., as stated in the request metadata.
- Track actual rent collections, the repayment of the estimated $2 million in COVID-related deferrals, and any additional concessions or tenant defaults.
- Review available borrowing capacity, debt covenants, debt maturities, interest-rate exposure, and the effect of swap valuations and LIBOR transition.
- Assess whether acquisitions close as planned and whether financing remains available on acceptable terms; distinguish completed purchases from properties under contract.
- Monitor dividend coverage and the credit-facility restriction limiting common distributions to 95% of AFFO beginning at the end of Q4 2020.
- Evaluate the potential internalization transaction, including its cost, timing, and required approvals. FFO and AFFO are non-GAAP measures and may not be comparable with other REITs.